Amryt has started a phase three trial for a potential treatment for a rare genetic skin  disorder. Photograph: iStock

Amryt Pharma, the orphan drug development company that was subject to a reverse takeover of former oil and gas group Fastnet last year, posted €1.35 m(...)

Amryt is now primarily focused on going into clinical trials on a potential therapy for a treatment for a rare, debilitating hereditary skin disorder called epidermolysis bullosa

Amryt Pharmaceutical, the orphan drug development business that was subject to a reverse takeover by former oil and gas group Fastnet earlier this yea(...)

Amryt is now focused on clinical trials on a potential therapy for a rare skin disorder called epidermolysis bullosa

Amryt Pharmaceutical, the orphan drug development business that was subject to a reverse takeover by oil and gas group Fastnet, has updated the market(...)